Results 81 to 90 of about 17,845 (225)

Upper Airway Obstruction due to Kaposi Sarcoma—Presenting Sign of HIV: Case Report and Review

The Laryngoscope, Volume 136, Issue 6, Page 2631-2637, June 2026.
This study presents a case of undiagnosed HIV presenting with Kaposi sarcoma (KS) of the head and neck with acute upper airway obstruction (UAO) and provides an updated scoping literature review to examine the patient characteristics, lesion characteristics, interventions, and outcomes of KS cases with UAO from the pharynx, larynx, and/or trachea.
Zachary A. Wykoff, Logan F. McColl, Robert A. Baiocchi, Matthew O. Old   +3 more
wiley   +1 more source

Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia

PLoS ONE
Background Immuno-hematological abnormalities are common among HIV infected individuals as well as patients with highly active antiretroviral therapy (HAART).
Ayantu Gudina, Moges Wordofa, Fekadu Urgessa   +2 more
semanticscholar   +1 more source

O papel do dolutegravir na terapia antiretroviral

, 2019
Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus.
Vieira, Tamyres dos Santos, Moura, Letícia Coutinho Lopes, Vieira, Isabela dos Santos, Moura, Marcos de Assis, Bresser, Matheus   +4 more
core   +1 more source

Dolutegravir in Real Life: self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho

, 2022
Pseudonymized dataset for the accepted manuscript "Dolutegravir in Real Life: self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in ...
Jennifer M. Belus, Alain Amstutz, Kuena Mokhele, Niklaus D. Labhardt, Nsakala, B. L., Rakuoane, I., Belus, J. M., Jennifer A. Brown, Tracy R. Glass, Glass, T. R., Mokhele, K., Josephine Muhairwe, Tschumi, N., Itumeleng Rakuoane, Klimkait, T., Bienvenu L. Nsakala, Labhardt, N. D., Thomas Klimkait, Nadine Tschumi, Amstutz, A., Brown, J. A., Muhairwe, J.   +21 more
core   +1 more source

Treatment durability, satisfaction and quality of life in virologically suppressed HIV‐1 people switching to doravirine: Results from the French study DoraVIH

HIV Medicine, Volume 27, Issue 6, Page 886-895, June 2026.
Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno, Robineau Olivier, Pourcher Valérie, Loubet Paul, Palacios Christia, Jacomet Christine, Benachir Haydar, Mariot Philippe, Parienti Jean‐Jacques, Slama Laurence   +9 more
wiley   +1 more source

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study

Journal of the International AIDS Society
Dolutegravir (DTG) is widely used for antiretroviral therapy (ART). We compared weight and blood pressure trends and examined the association between high blood pressure and weight gain among people living with HIV (PLHIV) switching to or starting DTG ...
T. Shamu, M. Egger, T. Mudzviti, C. Chimbetete, J. Manasa, N. Anderegg   +5 more
semanticscholar   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, Volume 27, Issue 6, Page 965-978, June 2026.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Dolutegravir based therapy showed CD4+ T cell count recovery and viral load suppression among ART naïve people living with HIV AIDS: a pilot evaluation

Scientific Reports
Recently, dolutegravir (DTG)-based combined therapy, a more effective and safer first-line antiretroviral therapy (ART), has been recommended by the World Health Organization for the treatment of Human Immunodeficiency Virus (HIV) since July 2018 ...
Teshager Gebremedhin, Melak Aynalem, Mohammed Adem, D. Geremew, Yetemwork Aleka, A. Kiflie   +5 more
semanticscholar   +1 more source

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine

Antiviral Therapy
Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD ...
Micol Pallanza, Paul Thoueille, Myriam Briki, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini   +5 more
doaj   +1 more source

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Southern African Journal of HIV Medicine, 2020
Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment ...
Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes   +5 more
doaj   +1 more source